Abstract Number: 8 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome
Background/Purpose Long term anticoagulation is recommended in antiphospholipid syndrome with thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K antagonists,…Abstract Number: 7 • 2014 ACR/ARHP Annual Meeting
Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients
Background/Purpose To investigate the beneficial effects of in vivoubiquinol (Q) supplementation on athero-thrombosis prevention in APS patients. Methods The study was performed on 10 APS…Abstract Number: 6 • 2014 ACR/ARHP Annual Meeting
Performance Evaluation and Clinical Associations of the Aphl ELISA Compared to Criteria Antiphospholipid Immunoassays in Lupus Patients
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by recurrent thrombotic and obstetric manifestations in the presence of ‘criteria' antiphospholipid antibodies (aPL) [anticardiolipin (aCL), anti-β2glycoproteinI (anti-β2GPI )…Abstract Number: 5 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet…Abstract Number: 4 • 2014 ACR/ARHP Annual Meeting
Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Background/Purpose: Several studies suggested that antibodies to Domain 1 of beta2glycoprotein I (a-B2GPI-D1) represent a promising biomarker for the diagnosis and risk assessment of Antiphospholipid…Abstract Number: 3 • 2014 ACR/ARHP Annual Meeting
Is There an Association Between Persistently High Positive Antiphospholipid Antibody Profile and Organ Damage Accrual in Lupus Patients?
Background/Purpose: Few studies assessed the impact of antiphospholipid antibodies (aPL) on organ damage in lupus with conflicting results. Our objective was to determine if persistently…Abstract Number: 2 • 2014 ACR/ARHP Annual Meeting
Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis
Background/Purpose: Antiphospholipid-associated syndrome refers to organ dysfunctions developed in the existence of antiphospholipid antibodies (aPL), apart from the typical manifestations of antiphospholipid syndrome (APS) such…Abstract Number: 16 • 2014 ACR/ARHP Annual Meeting
Differential Assay Reactivity of IgA Anti-B2glycoprotein I Antibodies: Implications for Clinical Interpretation of Antiphospholipid Antibody Testing
Background/Purpose: IgA anti-β2Glycoprotein I (aβ2GPI) antibodies remain controversial in the assessment of thrombotic risk in spite of several studies indicating an association with thromboembolic…Abstract Number: 11 • 2014 ACR/ARHP Annual Meeting
Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome
Background/Purpose: The current recommended anti-thrombotic therapy for patients with anti-phospholipid syndrome (APS) is oral anticoagulants with an INR intensity between 2-3. This recommendation has been…Abstract Number: L7 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome without Anticoagulation: 0utcome of 50 Patients
Background/Purpose: Long-term anticoagulation is currently the standard treatment for arterial or venous antiphospholipid syndrome (APS). However, in daily clinical practice, the question of withdrawing anticoagulation…Abstract Number: L21 • 2014 ACR/ARHP Annual Meeting
Striking Discrepancy in the Development of Anti-Drug Antibodies (ADA) in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) in Response to Infliximab (INF) and Its Biosimilar CT-P13
Background/Purpose: The differences between RA and AS have been recently highlighted (1). There is evidence that there are major clinical, pathophysiological and genetic differences. In…Abstract Number: L17 • 2014 ACR/ARHP Annual Meeting
Bariatric Surgery Improves Rheumatoid Arthritis Disease Activity, Reduces Inflammatory Markers, and Decreases Medication Usage
Background/Purpose: Obesity causes a chronic inflammatory state. Increased body mass index (BMI) is associated with incident rheumatoid arthritis (RA) and may impact RA disease activity.…Abstract Number: L1 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Background/Purpose: Secukinumab, a human anti–IL-17A monoclonal antibody, has shown efficacy in the treatment of psoriasis in phase 3 studies with subcutaneous (s.c.) dosing as well…Abstract Number: L6 • 2014 ACR/ARHP Annual Meeting
A PHASE 2, Randomized, Double-Blind Comparison of the Efficacy and Safety of PF-04171327 (1, 5, 10, 15 mg QD) Vs 5 and 10 Mg Prednisone QD or Placebo in Subjects with Rheumatoid Arthritis (RA) over 8 Weeks Followed By a 4-Week Taper of Study Drug
Background/Purpose: PF-04171327 is a dissociated agonist of the glucocorticoid receptor (DAGR), a selective high-affinity partial agonist of the GR with potent anti-inflammatory activity at exposures…Abstract Number: L5 • 2014 ACR/ARHP Annual Meeting
Improvement of Disease Activity and Reduction of Severe Flares Following Subcutaneous Administration of an IL-6 Monoclonal Antibody (mAb) in Subjects with Active Generalized Systemic Lupus Erythematosus (SLE)
Background/Purpose: PF-04236921 is a fully human mAb that binds to circulating IL-6 and neutralizes its activity. This may be beneficial in reducing the disease…
ACR Meeting Abstracts